Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
Fumarola C, Bozza N, Castelli R, Ferlenghi F, Marseglia G, Lodola A, Bonelli M, La Monica S, Cretella D, Alfieri R, Minari R, Galetti M, Tiseo M, Ardizzoni A, Mor M, Petronini PG. Fumarola C, et al. Among authors: cretella d. Front Oncol. 2019 Mar 26;9:179. doi: 10.3389/fonc.2019.00179. eCollection 2019. Front Oncol. 2019. PMID: 30972293 Free PMC article.
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.
Digiacomo G, Fumarola C, La Monica S, Bonelli MA, Cretella D, Alfieri R, Cavazzoni A, Galetti M, Bertolini P, Missale G, Petronini PG. Digiacomo G, et al. Among authors: cretella d. Front Oncol. 2020 Sep 23;10:563249. doi: 10.3389/fonc.2020.563249. eCollection 2020. Front Oncol. 2020. PMID: 33072590 Free PMC article.
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Quaini F, Graiani G, Madeddu D, Mozzoni P, Galvani E, La Monica S, Bonelli M, Fumarola C, Mutti A, Carbognani P, Tiseo M, Barocelli E, Petronini PG, Ardizzoni A. Cavazzoni A, et al. Among authors: cretella d. Mol Cancer. 2012 Dec 12;11:91. doi: 10.1186/1476-4598-11-91. Mol Cancer. 2012. PMID: 23234355 Free PMC article.
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR. La Monica S, et al. Among authors: cretella d. PLoS One. 2013 Oct 22;8(10):e78656. doi: 10.1371/journal.pone.0078656. eCollection 2013. PLoS One. 2013. PMID: 24167634 Free PMC article.
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Bonelli MA, Cavazzoni A, Saccani F, Alfieri RR, Quaini F, La Monica S, Galetti M, Cretella D, Caffarra C, Madeddu D, Frati C, Lagrasta CA, Falco A, Rossetti P, Fumarola C, Tiseo M, Petronini PG, Ardizzoni A. Bonelli MA, et al. Among authors: cretella d. Mol Cancer Ther. 2015 Aug;14(8):1916-27. doi: 10.1158/1535-7163.MCT-14-0892. Epub 2015 May 26. Mol Cancer Ther. 2015. PMID: 26013318
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Galetti M, Petronini PG, Fumarola C, Cretella D, La Monica S, Bonelli M, Cavazzoni A, Saccani F, Caffarra C, Andreoli R, Mutti A, Tiseo M, Ardizzoni A, Alfieri RR. Galetti M, et al. Among authors: cretella d. PLoS One. 2015 Nov 4;10(11):e0141795. doi: 10.1371/journal.pone.0141795. eCollection 2015. PLoS One. 2015. PMID: 26536031 Free PMC article.
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
La Monica S, Madeddu D, Tiseo M, Vivo V, Galetti M, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Falco A, Gervasi A, Lagrasta CA, Naldi N, Barocelli E, Ardizzoni A, Quaini F, Petronini PG, Alfieri R. La Monica S, et al. Among authors: cretella d. J Thorac Oncol. 2016 Jul;11(7):1051-63. doi: 10.1016/j.jtho.2016.03.006. Epub 2016 Mar 19. J Thorac Oncol. 2016. PMID: 27006151 Free article.
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.
Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E. Cavazzoni A, et al. Among authors: cretella d. Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881794 Free PMC article.
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.
Fumarola C, Cretella D, La Monica S, Bonelli MA, Alfieri R, Caffarra C, Quaini F, Madeddu D, Falco A, Cavazzoni A, Digiacomo G, Mazzaschi G, Vivo V, Barocelli E, Tiseo M, Petronini PG, Ardizzoni A. Fumarola C, et al. Among authors: cretella d. Oncotarget. 2017 Jul 17;8(54):91841-91859. doi: 10.18632/oncotarget.19279. eCollection 2017 Nov 3. Oncotarget. 2017. PMID: 29190880 Free PMC article.
42 results